SmallCapReview Adds Bioenvision and Radyne - SmallCapReview a leading small-cap stock information site, is pleased to announce that Bioenvision (Nasdaq: BIVN) and Radyne Corporation (Nasdaq: RADN) have been added as ``New Focus Stocks" Bioenvision (BIVN) primary focus is the acquisition, development and marketing of compounds and technologies for the treatment of cancer. Bioenvision has a broad pipeline of products for the treatment of cancer, including: Evoltra, Modrenal (for which Bioenvision has obtained regulatory approval for marketing in the United Kingdom for the treatment of post-menopausal breast cancer following relapse to initial hormone therapy), and other products. Bioenvision is also developing Suvus which is currently in clinical development for refractory chronic hepatitis C infection. The company also offers various anti-infective technologies, including the OLIGON technology, an advanced biomaterial that has been incorporated into various FDA approved medical devices. In addition, it provides an animal health product, Vetoryl, for the treatment of Cushing's disease in dogs; and Velostan, a cytostatic drug under investigation as an anticancer agent and as an antimicrobial.